Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Aruga, Atsushi; Takeshita, Nobuhiro; Kotera, Yoshihito; Okuyama, Ryuji; Matsushita, Norimasa; Ohta, Takehiro; Takeda, Kazuyoshi; Yamamoto, Masakazu

doi:10.1186/1479-5876-12-61

Cited by 70 publications

(50 citation statements)

References 25 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients had a peptide-specific T cell immune response, and stable disease was observed in 5 of 9 patients after 8 weeks of therapy. The median progression-free survival was 3.4 months and the median OS 9.7 months [92]. In another similar therapeutic situation 9 patients were treated with a four-peptide derived vaccine from cancer-testis antigens.…”

Section: Vaccination Strategies In Pdac and Extrahepatic Btcmentioning

confidence: 99%

Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer

2019

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) and extrahepatic biliary tract cancer (BTC) are among the malignancies with the highest morbidity and mortality. Despite increasing knowledge on biology and novel therapies, outcome remains poor in these patients. Recent progress in immunotherapies created new hopes in the treatment of PDAC and extrahepatic BTC. Several trials tested immunotherapies in various therapeutic situations as monotherapies or in combinations. Although responses were seen in some of the trials, the value of immunotherapy in PDAC and extrahepatic BTC remains unclear in the current situation, especially regarding the complex biological characteristics with a high stroma component, intrinsic resistance mechanisms and an immunosuppressive, hypoxic microenvironment. These major hurdles have to be taken into account and overcome if immunotherapies should be successful in these tumor entities. Thereby, combinational approaches that allow on the one hand targeted therapy and on the other restore or boost the function of immune cells are promising.

show abstract

Section: Vaccination Strategies In Pdac and Extrahepatic Btcmentioning

confidence: 99%

Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer

2019

View full text Add to dashboard Cite

show abstract

“…The median OS was 9.7 months. Whilst modest, an OS of 9.7 months following chemotherapy in refractory disease warrants further evaluation in phase II/III studies [39].…”

Section: Role Of Stimulatory Immunotherapies Such As Vaccines In Btcmentioning

confidence: 99%

Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets

Tariq¹,

Vogel²,

McNamara³

et al. 2018

Oncol Res Treat

View full text Add to dashboard Cite

There is a well-established link between biliary tract cancers (BTC) and chronic inflammatory conditions such as primary sclerosing cholangitis, chronic cholecystitis, chronic cholelithiasis, liver fluke-associated infestations, and chronic viral hepatic infections. These associated risk factors highlight the potential for development of immune-modulatory agents in this poor-prognostic disease group with limited treatment options. Clinical trials have evaluated the role of immune cells, inflammatory biomarkers, vaccines, cytokines, adoptive cell therapy, and immune checkpoint inhibitors in patients with BTC. Although these have demonstrated the importance of the immune environment in BTC, currently none of the immune-based therapies have been approved for use in this disease group. The role of immunomodulatory agents is a developing field and has yet to find its way ‘from bench to bedside' in BTC.

show abstract

“…These small studies have been well tolerated without showing a strong signal of efficacy [54,55] . For example, Aruga et al [56] conducted a small phase I clinical trial evaluating multiple-peptide vaccination for patients with advanced BTC. Peptide-specific T-cell immune responses and disease stability were observed in some patients.…”

Section: Biliary Tract Carcinomasmentioning

confidence: 99%

Treating Hepatobiliary Cancer: The Immunologic Approach

Duffy

Greten²

2017

Dig Dis

View full text Add to dashboard Cite

Hepatobiliary cancer comprises a heterogeneous group of malignancies in which the standard treatments for advanced disease are minimally effective and evolve slowly over time. Like the majority of gastrointestinal cancers, with some notable exceptions, the impact of immune-based approaches is yet to be experienced. Notwithstanding this, the etiological background of hepatobiliary cancer - overlapping in almost every known causative or associated factor with inflammation - provides a strong clue that these approaches may have an impact on this group of diseases. This review seeks to put the management of hepatobiliary cancers in the context of its inflammation-based etiology, with the aim of pointing to the therapeutic opportunities in immune-based approaches currently entering the clinic or those that are about to do so.

show abstract

Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Cited by 70 publications

References 25 publications

Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer

Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer

Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets

Treating Hepatobiliary Cancer: The Immunologic Approach

Contact Info

Product

Resources

About